Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results

By Reuters News

- Cumberland Pharmaceuticals Inc. CPIX.O:

  • CUMBERLAND PHARMACEUTICALS ANNOUNCES ASSIST-SSC TRIAL TOP-LINE RESULTS

  • CUMBERLAND PHARMACEUTICALS - IFETROBAN DEMONSTRATES SAFETY AND TOLERABILITY IN SYSTEMIC SCLEROSIS PATIENTS

  • CUMBERLAND PHARMACEUTICALS - IFETROBAN WELL TOLERATED; MOST GI ADVERSE EVENTS WERE MILD AND RESOLVED

  • CUMBERLAND PHARMACEUTICALS - NO SERIOUS ADVERSE EVENT RELATED TO IFETROBAN DURING 12-MONTH TREATMENT PERIOD

  • CUMBERLAND PHARMACEUTICALS - MODEST INCREASE IN MILD BLEEDING-RELATED ADVERSE EVENTS WITH IFETROBAN

Further company coverage: CPIX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.